August 9, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

The National Institute of Neurological Disorders and Stroke and SymBio
Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity ofbrincidofovir (BCV) against Epstein Barr virus (EBV)TOKYO, Japan, August 8, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “theCompany”) today announced that it has entered into a collaboration agreement (the “Agreement”)
with the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the National
Institutes of Health (NIH) in the United States, for the transfer of materials for evaluation of BCV’spotential antiviral effect on Epstein Barr virus (EBV).
Under the Agreement. SymBio will transfer BCV IV to NINDS, who will conduct preclinical studies toevaluate BCV’s antiviral effect on EBV.
Statement from Mr. Fuminori Yoshida, President and CEO of SymBio: "Through this collaboration
with NINDS, we hope that the high antiviral effect of BCV IV against the EB virus will help us tounderstand the possibility of intervening in the disease progression of multiple sclerosis by targetingthe EB virus, which is a major cause of multiple sclerosis.
The Company does not expect the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 31, 2022.
[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

1About the anti-viral drug Brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approvedand marketed in the United States and the European Union, but unapproved in Japan. As BCV
exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV,
BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as
herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BKvirus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent
that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. SymBio entered into
an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix")for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants
SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all humanindications, excluding the prevention and treatment of orthopox infections (which includes smallpoxand monkeypox). To develop global operations, the Company is considering partnerships that will
utilize regional characteristics of the target diseases, and striving to maximize the business value ofthe products and to deliver to patients who need our products as soon as possible. The Company aims
to serve the patients not only in Japan but also in Europe and the U.S. market where the market sizefor organ transplantation is large, and Asia, including the Chinese market.

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio
Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Carolyn Yanavich).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2